Skip to main content

Table 1 Cardiac function of experimental groups

From: Improvement of cardiac function by placenta-derived mesenchymal stem cells does not require permanent engraftment and is independent of the insulin signaling pathway

  

Experimental groups

Parameters

Time, daysa

Sham (n = 11)

cp-MSCs (n = 11)

Placebo (n = 8)

Ejection fraction, %

-22

57.5 ± 3.6

59.5 ± 5.6

59.3 ± 3.6

-1

50.2 ± 1.7

28.7 ± 2.1b

27.4 ± 2.6b

7

49.8 ± 2.4

34.3 ± 3.1

26.4 ± 3.0

15

50.9 ± 2.6

33.8 ± 1.9

22.9 ± 2.4c

23

48.3 ± 1.8

31.2 ± 3.1

24.6 ± 2.6

39

46.2 ± 2.6

33.8 ± 2.3

22.2 ± 2.1d

End-systolic volume, μL

-22

24.4 ± 3.9

23.3 ± 7.4

17.7 ± 3.8

-1

31.3 ± 2.3

61.4 ± 4.7b

67.2 ± 5.5b

7

31.6 ± 2.7

55.5 ± 6.2

62.4 ± 7.3

15

34.35 ± 3.4

60.4 ± 5.3

75.8 ± 6.8c

23

34.5 ± 2.2

64.6 ± 6.5

77.2 ± 6.4

39

34.7 ± 3.5

58.3 ± 7.9

80.7 ± 8.5c

End-diastolic volume, μL

-22

56.3 ± 4,9

54.8 ± 9.5

53.8 ± 8.5

-1

62.3 ± 3.4

84.2 ± 4.3b

92.0 ± 4.8b

7

62.6 ± 4.2

82.5 ± 5.6

90.9 ± 7.9

15

68.6 ± 4.2

90.6 ± 6.9

98.0 ± 6.9

23

67.2 ± 3.9

91.8 ± 6.1

102.6 ± 7.3

39

63.6 ± 4.2

89.9 ± 9.2

104.3 ± 9.6

  1. aDay -22 shows baseline values (before myocardial infarction) for all groups. Day -1 shows data before treatment with either chorionic plate mesenchymal stem cells (cp-MSCs) or placebo. bP <0.05 compared with Sham. cP <0.05, dP <0.01 comparing cp-MSCs versus placebo.